| Submit your comments on this article |
| Science & Technology |
| Global Hydroxychloroquine Study To Resume After Positive Trial Results |
| 2020-07-01 |
| UK regulators have approved the resumption of a global trial aimed at determining whether hydroxychloroquine and chloroquine are effective in preventing COVID-19 infections in healthcare settings, according to Reuters. The trial, known as COPCOV, was paused after another British study found the drugs to be ineffective in treating the virus, however the Medicines and Healthcare Products Regulatory Agency (MHRA) has now allowed the research to resume following positive COPCOV trial results. "Participants will take the study drugs each day for a period of three months, and will be followed closely to see how well the drug is tolerated, whether they contract the virus, and if they do, whether they develop mild or more severe COVID-19," according to Tropical Health Network. According to Reuters, COPCOV is a "randomised, placebo-controlled trial that is aiming to enrol 40,000 healthcare workers and other at-risk staff around the world," conducted by Oxford University's Bangkok-based Mahidol Oxford Tropical Medicine Research Unit (MORU). The study is funded in part by the Bill & Melinda Gates Foundation. Unsurprisingly, their website makes no mention of the inclusion of zinc - largely credited by pro-HCQ physicians as the key ingredient to the treatment. Related: Hydroxychloroquine: 2020-06-30 Gilead sets pricing for coronavirus drug remdesivir, could cost over $3G Hydroxychloroquine: 2020-06-21 US halts test of Trump-touted hydroxychloroquine for COVID-19 patients Hydroxychloroquine: 2020-06-17 New York police pulled from prosecutors' offices after DA declined to charge protesters: report Related: Oxford University: 2020-06-20 Black Lives Matter protests: Oxford Chancellor attacks 'hypocrisy' of Rhodes scholars calling to remove statue Oxford University: 2020-05-30 New hydroxychloroquine study: Early outpatient treatment is the most effective for treatment of COVID-19 patients, Dr. Harvey A Risch of Yale University says Oxford University: 2020-03-27 COVID19 update, March 26, 2020: antibody testing could be a game changer |
| Posted by:Iblis |
| #11 |
| Posted by: 49 Pan 2020-07-01 18:35 |
| #10 |
| Posted by: Mullah Richard 2020-07-01 07:56 |
| #9 |
| Posted by: g(r)omgoru 2020-07-01 07:10 |
| #8 |
| Posted by: Elmerert Hupens2660 2020-07-01 07:06 |
| #7 |
| Posted by: Clem 2020-07-01 06:58 |
| #6 |
| Posted by: g(r)omgoru 2020-07-01 05:54 |
| #5 |
| Posted by: Bright Pebbles 2020-07-01 05:39 |
| #4 |
| Posted by: g(r)omgoru 2020-07-01 04:23 |
| #3 |
| Posted by: Bright Pebbles 2020-07-01 04:10 |
| #2 |
| Posted by: g(r)omgoru 2020-07-01 03:05 |
| #1 |
| Posted by: Clem 2020-07-01 00:23 |